Cite
HARVARD Citation
Lei, J. et al. (n.d.). 56O A randomized, controlled, multicenter phase II trial of camrelizumab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant treatment in resectable stage IIIA and IIIB (T3N2) non-small-cell lung cancer. Immuno-oncology technology. p. . [Online].